Adelphi Group

Bioclinica | September 10, 2020

Bioclinica, an integrated solutions provider of clinical life science and technology expertise, delivering powerful insight into clinical trial development in bringing new therapies to people worldwide, announced today that Direct Biologics, a market leading innovator and science-based manufacturer of regenerative products, will leverage Bioclinica's Interactive Response Technology (IRT) for their EXIT COVID-19 study — a multi-center FDA phase II clinical trial for the use of ExoFlo&tr...

BioSpace | March 20, 2020

EcoGen Laboratories ("EcoGen"), the leading vertically-integrated manufacturer and supplier of high quality hemp genetics, hemp-derived specialty ingredients and finished products in North America, released the following statement today from the Company's Co-Founder and CEO Alexis Korybut regarding operational updates amid the COVID-19 pandemic....

BioSpace | March 24, 2020

Axim Biotech® Inc. (OTCQB: AXIM) (“AXIM® Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting oncological and cannabinoid research, announced today that its subsidiary Sapphire Biotech, Inc. (“Sapphire”) has completed pre-clinical drug studies on a new compound, SPX-1009, demonstrating 10 times greater potency than its parent compound, SBI-183, in inhibiting metastasis....

MEDICAL

Palatin Technologies, Inc | December 29, 2021

Palatin Technologies, Inc. a specialized biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, announced the initiation of the pivotal Phase 3 MELODY-1 clinical study of PL9643 in patients with dry eye disease. The study is designed to enroll up to 400 patients at multiple U.S. sites, and top-line results are currently expected second half calendar 2022. "W...